Company Overview - Allstate (ALL) closed at $174.83, with a daily increase of +0.26%, underperforming the S&P 500's gain of 1.08% [1] - Over the past month, Allstate's shares have increased by 8.64%, outperforming the Finance sector's decline of 2.72% and the S&P 500's gain of 0.43% [1] - The company is set to announce its earnings on July 31, 2024, with an expected EPS of -$0.53, indicating an 88.01% growth year-over-year, and projected revenue of $15.56 billion, up 10.09% from the prior-year quarter [1] Earnings Estimates - Full-year Zacks Consensus Estimates predict earnings of $12.72 per share and revenue of $62.7 billion, reflecting year-over-year changes of +1238.95% and +9.24%, respectively [2] - Recent analyst estimate revisions indicate optimism regarding Allstate's business and profitability, which are correlated with near-term share price momentum [2] Valuation Metrics - Allstate currently has a Forward P/E ratio of 13.71, compared to the industry average of 12.6, suggesting it is trading at a premium [3] - The company's PEG ratio stands at 1.96, while the Insurance - Property and Casualty industry has an average PEG ratio of 1.6 [3] Industry Context - The Insurance - Property and Casualty industry is part of the Finance sector and holds a Zacks Industry Rank of 71, placing it in the top 29% of over 250 industries [4] - The Zacks Industry Rank assesses the strength of industry groups, with top-rated industries outperforming the bottom half by a factor of 2 to 1 [4]

The most recent trading session ended with Allstate (ALL) standing at $166.91, reflecting a +1.97% shift from the previouse trading day's closing. The stock outperformed the S&P 500, which registered a daily gain of 0.28%. At the same time, the Dow added 0.53%, and the tech-heavy Nasdaq gained 0.4%.Shares of the insurer witnessed a gain of 4.21% over the previous month, beating the performance of the Finance sector with its loss of 2.84% and the S&P 500's gain of 3.78%.The investment community will be close ...

Allstate (ALL) closed the most recent trading day at $159.54, moving +0.7% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.1%. At the same time, the Dow lost 0.08%, and the tech-heavy Nasdaq gained 0.28%.Shares of the insurer have depreciated by 4.02% over the course of the past month, underperforming the Finance sector's gain of 1.14% and the S&P 500's gain of 4.08%.The investment community will be paying close attention to the earnings performance ...

In the latest trading session, Allstate (ALL) closed at $162.41, marking a +1.18% move from the previous day. This move outpaced the S&P 500's daily loss of 0.31%. At the same time, the Dow added 0.67%, and the tech-heavy Nasdaq lost 1.09%.The insurer's shares have seen a decrease of 2.63% over the last month, not keeping up with the Finance sector's loss of 1.77% and the S&P 500's gain of 2.73%.The investment community will be closely monitoring the performance of Allstate in its forthcoming earnings repor ...

Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.Cash flow can come from bond interest, interest from other types of investments, and of course, dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by its dividend yield, a metric that ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Allstate (ALL) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Allstate currently has an average brokerage recommendation (ABR) ...

Preparing for retirement is vital to building a nest egg that will provide financial stability for many years. One of the best ways to reach this goal is to find retirement stocks to buy now and begin long-term investing at an early age in strong companies that provide impressive returns in share price and dividend appreciation.Investing for retirement may not be the most exciting endeavor, but implementing as many long-term investing strategies as possible will drastically improve overall financial indepen ...

LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces three abstracts to be presented at the European Hematology Association (EHA) Congress, June 13-16, 2024. “We are looking forward to presenting longer-term data from adult patients with r/r ALL treated with obe-cel in the FELIX study,” said Dr. Christian Itin, Chief Executive Officer of Autolus. “The data indicate ...

Allstate (ALL) closed the most recent trading day at $160.63, moving -0.6% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 0.85%. Elsewhere, the Dow saw a downswing of 0.09%, while the tech-heavy Nasdaq appreciated by 1.53%.Shares of the insurer witnessed a loss of 4.42% over the previous month, trailing the performance of the Finance sector with its loss of 1.12% and the S&P 500's gain of 3.11%.The upcoming earnings release of Allstate will be of great int ...

Shawn Williams/iStock Editorial via Getty ImagesInvestment Thesis Currently, Allstate (NYSE:ALL) is on the cusp of heightened growth. With COVID putting a damper on the international economy, its hardening effects on the reinsurance market and the resulting temporary effects on the insurance market are largely overstated, leaving it an undervalued industry. Through this paper, we will reveal additional reasons why the Insurance industry is undervalued, with Allstate being the best value investment from ...